AAPL343.91-3.82 (-1.10%) ▼|ABBV286.74+1.10 (+0.39%) ▲|ABT104.88+1.18 (+1.14%) ▲|ACN247.23-2.14 (-0.86%) ▼|ADBE258.62-5.20 (-1.97%) ▼|AMAT387.59+10.35 (+2.74%) ▲|AMD531.28+14.49 (+2.80%) ▲|AMGN444.63+5.37 (+1.22%) ▲|AMT188.28-0.69 (-0.37%) ▼|AMZN249.09+1.09 (+0.44%) ▲|AVGO329.17+7.49 (+2.33%) ▲|AXP315.05+1.83 (+0.58%) ▲|BA188.31-0.04 (-0.02%) ▼|BAC50.52-0.04 (-0.08%) ▼|BKNG153.14-2.69 (-1.73%) ▼|BLK1,127.66+9.41 (+0.84%) ▲|BMY61.61+0.13 (+0.21%) ▲|BNY147.18+2.54 (+1.76%) ▲|BRK-B548.56+6.37 (+1.17%) ▲|C121.04+0.42 (+0.35%) ▲|CAT692.13+6.76 (+0.99%) ▲|CL93.10-0.94 (-1.00%) ▼|CMCSA22.05-0.64 (-2.82%) ▼|COF202.35+1.01 (+0.50%) ▲|COP151.37+0.57 (+0.38%) ▲|COST1,005.16+1.84 (+0.18%) ▲|CRM247.61-0.96 (-0.39%) ▼|CSCO110.24+3.74 (+3.51%) ▲|CVS92.53-0.94 (-1.01%) ▼|CVX232.01-1.20 (-0.51%) ▼|DE641.25-4.90 (-0.76%) ▼|DHR232.97+2.47 (+1.07%) ▲|DIS110.40-2.12 (-1.88%) ▼|DUK124.44-0.54 (-0.43%) ▼|EMR161.70+0.11 (+0.07%) ▲|FDX300.58+1.86 (+0.62%) ▲|GD357.04+7.68 (+2.20%) ▲|GE288.43+2.79 (+0.98%) ▲|GEV855.12+40.12 (+4.92%) ▲|GILD158.69+2.65 (+1.70%) ▲|GM76.31+0.39 (+0.51%) ▲|GOOG314.19-3.09 (-0.97%) ▼|GOOGL316.80-3.41 (-1.06%) ▼|GS893.28+17.60 (+2.01%) ▲|HD319.38-0.45 (-0.14%) ▼|HON219.28-1.87 (-0.85%) ▼|IBM253.44-0.12 (-0.05%) ▼|INTC90.47+3.51 (+4.04%) ▲|INTU339.89-3.50 (-1.02%) ▼|ISRG451.63-0.66 (-0.15%) ▼|JNJ266.30+2.49 (+0.94%) ▲|JPM334.04+2.46 (+0.74%) ▲|KO92.70-0.01 (-0.01%) ▼|LIN507.56-1.27 (-0.25%) ▼|LLY1,279.14+5.68 (+0.45%) ▲|LMT635.20+31.02 (+5.13%) ▲|LOW198.22-0.46 (-0.23%) ▼|LRCX237.50+7.40 (+3.22%) ▲|MA613.50-10.10 (-1.62%) ▼|MCD250.83+2.37 (+0.95%) ▲|MDLZ62.97-0.83 (-1.30%) ▼|MDT94.79-0.62 (-0.65%) ▼|META630.56-12.06 (-1.88%) ▼|MMM172.79-0.67 (-0.39%) ▼|MO73.62-0.69 (-0.93%) ▼|MRK140.61-4.66 (-3.21%) ▼|MS183.49+4.00 (+2.23%) ▲|MSFT532.60+8.09 (+1.54%) ▲|MU903.70+26.15 (+2.98%) ▲|NEE82.04-0.06 (-0.07%) ▼|NFLX63.90-1.95 (-2.96%) ▼|NKE37.91+0.61 (+1.64%) ▲|NOW158.18-0.78 (-0.49%) ▼|NVDA216.00+5.04 (+2.39%) ▲|ORCL126.06-0.10 (-0.08%) ▼|PEP135.46-0.31 (-0.23%) ▼|PFE29.79-0.24 (-0.80%) ▼|PG159.92-1.10 (-0.68%) ▼|PLTR198.84+2.09 (+1.06%) ▲|PM201.87+2.40 (+1.20%) ▲|QCOM179.60+3.69 (+2.10%) ▲|RTX197.48+6.47 (+3.39%) ▲|SBUX102.69+1.89 (+1.88%) ▲|SCHW89.73-0.85 (-0.94%) ▼|SO92.57-0.32 (-0.34%) ▼|SPG212.69+1.06 (+0.50%) ▲|T20.85-0.08 (-0.38%) ▼|TMO684.89+11.07 (+1.64%) ▲|TMUS146.93+0.39 (+0.27%) ▲|TSLA391.62+19.40 (+5.21%) ▲|TXN298.12+13.43 (+4.72%) ▲|UBER66.13-0.57 (-0.85%) ▼|UNH410.70-7.39 (-1.77%) ▼|UNP296.97+4.10 (+1.40%) ▲|UPS100.32-0.74 (-0.73%) ▼|USB59.70+0.12 (+0.20%) ▲|V404.16-3.76 (-0.92%) ▼|VZ43.10-1.56 (-3.49%) ▼|WFC82.65+0.26 (+0.32%) ▲|WMT120.29+0.40 (+0.33%) ▲|XOM184.54+1.33 (+0.73%) ▲|AAPL343.91-3.82 (-1.10%) ▼|ABBV286.74+1.10 (+0.39%) ▲|ABT104.88+1.18 (+1.14%) ▲|ACN247.23-2.14 (-0.86%) ▼|ADBE258.62-5.20 (-1.97%) ▼|AMAT387.59+10.35 (+2.74%) ▲|AMD531.28+14.49 (+2.80%) ▲|AMGN444.63+5.37 (+1.22%) ▲|AMT188.28-0.69 (-0.37%) ▼|AMZN249.09+1.09 (+0.44%) ▲|AVGO329.17+7.49 (+2.33%) ▲|AXP315.05+1.83 (+0.58%) ▲|BA188.31-0.04 (-0.02%) ▼|BAC50.52-0.04 (-0.08%) ▼|BKNG153.14-2.69 (-1.73%) ▼|BLK1,127.66+9.41 (+0.84%) ▲|BMY61.61+0.13 (+0.21%) ▲|BNY147.18+2.54 (+1.76%) ▲|BRK-B548.56+6.37 (+1.17%) ▲|C121.04+0.42 (+0.35%) ▲|CAT692.13+6.76 (+0.99%) ▲|CL93.10-0.94 (-1.00%) ▼|CMCSA22.05-0.64 (-2.82%) ▼|COF202.35+1.01 (+0.50%) ▲|COP151.37+0.57 (+0.38%) ▲|COST1,005.16+1.84 (+0.18%) ▲|CRM247.61-0.96 (-0.39%) ▼|CSCO110.24+3.74 (+3.51%) ▲|CVS92.53-0.94 (-1.01%) ▼|CVX232.01-1.20 (-0.51%) ▼|DE641.25-4.90 (-0.76%) ▼|DHR232.97+2.47 (+1.07%) ▲|DIS110.40-2.12 (-1.88%) ▼|DUK124.44-0.54 (-0.43%) ▼|EMR161.70+0.11 (+0.07%) ▲|FDX300.58+1.86 (+0.62%) ▲|GD357.04+7.68 (+2.20%) ▲|GE288.43+2.79 (+0.98%) ▲|GEV855.12+40.12 (+4.92%) ▲|GILD158.69+2.65 (+1.70%) ▲|GM76.31+0.39 (+0.51%) ▲|GOOG314.19-3.09 (-0.97%) ▼|GOOGL316.80-3.41 (-1.06%) ▼|GS893.28+17.60 (+2.01%) ▲|HD319.38-0.45 (-0.14%) ▼|HON219.28-1.87 (-0.85%) ▼|IBM253.44-0.12 (-0.05%) ▼|INTC90.47+3.51 (+4.04%) ▲|INTU339.89-3.50 (-1.02%) ▼|ISRG451.63-0.66 (-0.15%) ▼|JNJ266.30+2.49 (+0.94%) ▲|JPM334.04+2.46 (+0.74%) ▲|KO92.70-0.01 (-0.01%) ▼|LIN507.56-1.27 (-0.25%) ▼|LLY1,279.14+5.68 (+0.45%) ▲|LMT635.20+31.02 (+5.13%) ▲|LOW198.22-0.46 (-0.23%) ▼|LRCX237.50+7.40 (+3.22%) ▲|MA613.50-10.10 (-1.62%) ▼|MCD250.83+2.37 (+0.95%) ▲|MDLZ62.97-0.83 (-1.30%) ▼|MDT94.79-0.62 (-0.65%) ▼|META630.56-12.06 (-1.88%) ▼|MMM172.79-0.67 (-0.39%) ▼|MO73.62-0.69 (-0.93%) ▼|MRK140.61-4.66 (-3.21%) ▼|MS183.49+4.00 (+2.23%) ▲|MSFT532.60+8.09 (+1.54%) ▲|MU903.70+26.15 (+2.98%) ▲|NEE82.04-0.06 (-0.07%) ▼|NFLX63.90-1.95 (-2.96%) ▼|NKE37.91+0.61 (+1.64%) ▲|NOW158.18-0.78 (-0.49%) ▼|NVDA216.00+5.04 (+2.39%) ▲|ORCL126.06-0.10 (-0.08%) ▼|PEP135.46-0.31 (-0.23%) ▼|PFE29.79-0.24 (-0.80%) ▼|PG159.92-1.10 (-0.68%) ▼|PLTR198.84+2.09 (+1.06%) ▲|PM201.87+2.40 (+1.20%) ▲|QCOM179.60+3.69 (+2.10%) ▲|RTX197.48+6.47 (+3.39%) ▲|SBUX102.69+1.89 (+1.88%) ▲|SCHW89.73-0.85 (-0.94%) ▼|SO92.57-0.32 (-0.34%) ▼|SPG212.69+1.06 (+0.50%) ▲|T20.85-0.08 (-0.38%) ▼|TMO684.89+11.07 (+1.64%) ▲|TMUS146.93+0.39 (+0.27%) ▲|TSLA391.62+19.40 (+5.21%) ▲|TXN298.12+13.43 (+4.72%) ▲|UBER66.13-0.57 (-0.85%) ▼|UNH410.70-7.39 (-1.77%) ▼|UNP296.97+4.10 (+1.40%) ▲|UPS100.32-0.74 (-0.73%) ▼|USB59.70+0.12 (+0.20%) ▲|V404.16-3.76 (-0.92%) ▼|VZ43.10-1.56 (-3.49%) ▼|WFC82.65+0.26 (+0.32%) ▲|WMT120.29+0.40 (+0.33%) ▲|XOM184.54+1.33 (+0.73%) ▲|
15.3 C
New York
Tuesday, October 27, 2026

Tag: inhibitors

newsFORsourcecompanycontentinformation1releasesmarket

Riboscience Presents Phase 1a/b Overall Survival Data for ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination Therapy in Advanced Solid Tumors and Late-Line CRC

Median overall survival of 12 months with RBS2418 monotherapy in subjects with heavily pretreated tumors that express ENPP1 and cGAS proteins (TME-EG+ phenotype), versus...

Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy

Research Conducted at Tennessee Oncology's Greco-Hainsworth Centers for Research Contributes to Study Showing Longer Overall Survival with Next-Generation KRAS G12C TherapyNASHVILLE, Tenn., Oct. 25, 2026...

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor,...

New data on Lilly’s investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant...

Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across...

Ascletis’ Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne

- With first patient dosed in Phase III clinical trial, Ascletis' strategic partner Sagimet Biosciences Inc. ("Sagimet") advances denifanstat (ASC40)'s U.S. registrational program, building...

Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis

The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in ChinaCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 22, 2026...

ImmVira Presents Clinical Data from Three Bladder Cancer Studies at ESMO 2026

SUZHOU, China, Oct. 22, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its lead...

HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial

Oral HBI-8000 plus intravenous nivolumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with nivolumab alone, reducing the risk of...

Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™

Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S.FDA clearance of multiFiltratePRO and approval of dedicated...

OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors

— New Studies Expand Cesalatamig into Biomarker-driven Precision Immuno-oncology Strategies— Cesalatamig is Also Being Evaluated in Ongoing Phase 2 Studies in the United States and in...

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentationUpdated first-line...

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programsLatest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ®...

Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs,...

The neuroendocrine prostate cancer market is expected to grow steadily, driven by the rising recognition of NEPC as an aggressive and treatment-resistant form of...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInhibitors

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers